Posted by Michael Wonder on 02 Jan 2023
BeiGene announces acceptance of twelfth regulatory submission in China for PD-1 inhibitor tislelizumab
30 December 2022 - Submission seeks marketing authorisation for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
BeiGene announced that the Center for Drug Evaluation of the China NMPA has accepted a supplemental biologics license application for tislelizumab in patients with first-line unresectable or metastatic hepatocellular carcinoma.
